An updated SEER analysis demonstrates the prevalence of folks with second cancers is only increasing, from 18.4% of new cancer diagnoses less than a decade ago to 19.4% in 2019, again highlighting the need to reconsider prior malignancy as a common exclusion criteria in clinical trials. | Murphy, JAMA Oncol 2023
